LAVAL, QC, April 7, 2017 /CNW Telbec/ - Prometic Life
Sciences Inc. (TSX: PLI) (OTCQX: PFSCF) ("Prometic" or the "Corporation") announced today that it has received a $9.5 million purchase order for the supply of affinity resin to an existing client, a global leader in the
biopharmaceutical industry.
This purchase order is part of an ongoing license and long-term supply agreement already secured with the client. The affinity
resin will be manufactured by Prometic at its Isle of Man facility and supplied to the client starting in the second half of 2017
and continuing throughout 2018. Prometic's client is using the resin for large-scale purification of a therapeutic protein
product manufactured in large quantities.
Commenting on this latest purchase order, Mr. Pierre Laurin, President and Chief Executive
officer of Prometic said: "As much as we place great importance on our internal proprietary bioseparation capabilities to
develop, manufacture and commercialize our own impressive portfolio of high value plasma-derived therapeutics, we also continue
to work hard to grow our revenues from third party customers".
"This latest PO is evidence of the strength of our corporate relationships", said Dr. Steve
Burton, Prometic Bioseparations' Chief Executive Officer. "We expect our 2017 bioseparation revenues to be slightly ahead
of 2016 and then to nearly double in 2018".
About Prometic Life Sciences Inc.
Prometic Life Sciences Inc. (www.prometic.com) is a long
established biopharmaceutical company with globally recognized expertise in bioseparations, plasma-derived therapeutics and
small-molecule drug development. Prometic offers its state of the art technologies for large-scale purification of biologics,
drug development, proteomics and the elimination of pathogens to a growing base of industry leaders and uses its own affinity
technology that provides for highly efficient extraction and purification of therapeutic proteins from human plasma in order to
develop best-in-class therapeutics and orphan drugs. Prometic is also active in developing its own novel small-molecule
therapeutic products targeting unmet medical needs in the field of fibrosis, anemia, neutropenia, cancer and autoimmune
diseases/inflammation as well as certain nephropathies. Headquartered in Laval (Canada), Prometic
has R&D facilities in the UK, the U.S. and Canada, manufacturing facilities in the UK and commercial activities in the U.S.,
Canada, Europe, Russia, Asia
and Australia.
Forward Looking Statements
This press release contains forward-looking statements about Prometic's objectives, strategies and businesses that involve
risks and uncertainties. These statements are "forward-looking" because they are based on our current expectations about the
markets we operate in and on various estimates and assumptions. Actual events or results may differ materially from those
anticipated in these forward-looking statements if known or unknown risks affect our business, or if our estimates or assumptions
turn out to be inaccurate. Such risks and assumptions include, but are not limited to, Prometic's ability to develop,
manufacture, and successfully commercialize value-added pharmaceutical products, the availability of funds and resources to
pursue R&D projects, the successful and timely completion of clinical studies, the ability of Prometic to take advantage of
business opportunities in the pharmaceutical industry, uncertainties related to the regulatory process and general changes in
economic conditions. You will find a more detailed assessment of the risks that could cause actual events or results to
materially differ from our current expectations in Prometic's Annual Information Form for the year ended December 31, 2016, under the heading "Risk and Uncertainties related to Prometic's business". As a result, we
cannot guarantee that any forward-looking statement will materialize. We assume no obligation to update any forward-looking
statement even if new information becomes available, as a result of future events or for any other reason, unless required by
applicable securities laws and regulations. All amounts are in Canadian dollars unless indicated otherwise.
SOURCE ProMetic Life Sciences Inc.
To view the original version on PR Newswire, visit: http://www.newswire.ca/en/releases/archive/April2017/07/c3884.html